Últimas noticias sobre Starbox Group Hldgs (NASDAQ:STBX) Bolsa

Starbox Group Hldgs

Starbox Group Holdings Ltd engages in developing cash rebate, digital advertising, and payment solution business ecosystem targeting micro, small, and medium enterprises. Through the firm's subsidiaries in Malaysia, it connects retail merchants with retail shoppers to facilitate transactions through cash rebates offered by retail merchants, provide digital advertising services to advertisers, and provide payment solution services to merchants. Substantially all of its current operations are located in Malaysia. It operates in five segments include Cash rebate, payment solution, and media booking, Advertising services, Software licensing and Production services, Marketing and Promotional campaign services segment.

Starbox Group Holdings Ltd. - Class A Ordinary Shares

Starbox Group Holdings Ltd

Deutsche Bank analyst Scott Deuschle maintains Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) with a Buy and raises the price target from $184 to $215.

News

Price Target

Analyst Ratings

Deutsche Bank Maintains Buy on Boeing, Raises Price Target to $215

JP Morgan analyst Sebastiano Petti maintains BCE (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCE#TSX">BCE</a>) with a Neutral and lowers the price target from C$41 to C$35.

TSX:BCE

JP Morgan Maintains Neutral on BCE, Lowers Price Target to C$35

The Department Of Government Efficiency (D.O.G.E.) meme coin is gaining steam, with traders predicting further upward movement ahead of the eponymous government agency launching under <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42035165/coinbase-ceo-brian-armstrong-says-doge-department-is-a-once-in-a-lifetime-opprtunity-advocates-abolishing-individual-income-tax">the Trump administration</a>.
What Happened: Crypto trader Unipcs highlighted a reversal playing out for the meme coin, potentially setting the stage for the next rally. D.O.G.E is up 48% over the past 24 hours, trading around a valuation of $140 million.
After reaching all-time highs, D.O.G.E underwent an 82% correction over six weeks—a pattern commonly observed in meme coins.
This sharp decline followed a parabolic 4,000% rally within a month, which itself came after a two-month phase of correction and consolidation. 
Over the last month, the D.O.G.E. meme coin dropped 48.7%, reflecting market volatility but also laying the groundwork for a potential rebound.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42640482/dogecoin-turns-green-as-trump-appoints-loyalist-katie-miller-to-the-department-of-government-efficiency">Dogecoin Turns Green As Trump Appoints Loyalist Katie Miller To The Department Of Government Efficiency</a>
What's Next: The Department of Government Efficiency is poised to play a key role in shaping Trump's administration policies, drawing public attention and fostering narratives around efficiency and reform.
Traders anticipate the launch event could act as a major driver for both the Department of Government Efficiency meme coin and Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>), fueling speculative momentum and increasing visibility for both coins. 
Dogecoin is up 6.6% over the past 24 hours.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42469967/elon-musk-vivek-ramaswamy-slam-sec-just-another-weaponized-institution">Elon Musk, Vivek Ramaswamy Slam SEC: &#8216;Just Another Weaponized Institution&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

D.O.G.E. Zooms 48% Higher Ahead Of Elon Musk-Led Agency Launching In January: 'Ready For The Next Leg Up,' Millionaire Trader Vows

JP Morgan analyst Sebastiano Petti maintains TELUS (TSX:<a class="ticker" href="https://www.benzinga.com/stock/T#TSX">T</a>) with a Neutral and lowers the price target from C$23 to C$22.

TSX:T

JP Morgan Maintains Neutral on TELUS, Lowers Price Target to C$22

JP Morgan analyst Arun Jayaram maintains Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) with a Overweight and lowers the price target from $35 to $33.

JP Morgan Maintains Overweight on Halliburton, Lowers Price Target to $33

WIIM

TSLA

Tesla shares are trading lower following Q4 production and delivery data.

Tesla Q4 Total Production 459,445, Deliveries 495,570

Deutsche Bank analyst Scott Deuschle upgrades RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) from Hold to Buy and raises the price target from $131 to $140.

Upgrades

Deutsche Bank Upgrades RTX to Buy, Raises Price Target to $140

Tech

MLGO

MicroAlgo Announces Development Of A Hybrid Classical-Quantum Algorithm

Deutsche Bank analyst Scott Deuschle downgrades TransDigm Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>) from Buy to Hold and lowers the price target from $1444 to $1348.

Downgrades

Deutsche Bank Downgrades TransDigm Gr to Hold, Lowers Price Target to $1348

RDUS

Radius Pharmaceuticals Grants Pharmanovia Exclusive Commercialization Rights To Abaloparatide

General

LCID

SOUN

SoundHound AI And Lucid Announce Launch Of Lucid Assistant Voice Assistant

JP Morgan analyst Arun Jayaram maintains Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) with a Overweight and lowers the price target from $55 to $48.

JP Morgan Maintains Overweight on Schlumberger, Lowers Price Target to $48

Management

AWRE

Aware Appoints David Traverse As Interim CEO

Warren Buffett is one of the richest men in the world, yet his down-to-earth lifestyle is almost as famous as his fortune. He still grabs <a href="https://www.benzinga.com/personal-finance/24/11/42025535/warren-buffett-has-a-mcgold-card-granting-him-a-lifetime-of-free-food-thats-why-the-buffett-family-has-christmas-dinner-at-mcdonalds">McDonald's for breakfast</a>, lives in the same modest Omaha home he bought in the 1950s and, despite his billions, has never been one to spoil his kids.&nbsp;
Instead, he raised Howard, Susan and Peter with a clear philosophy: <a href="https://www.benzinga.com/personal-finance/24/10/41198368/warren-buffetts-son-who-famously-cashed-in-his-90-000-inheritance-at-19-spends-millions-in-buffe">they wouldn't inherit the bulk of his wealth</a>, but they would learn to earn, save and appreciate the value of hard work.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
</ul>
One of the best examples of this? Howard Buffett's teenage dream of owning a Corvette. As a Forbes article from 1998 (A Son's Advice to His Father) recounted, Warren's unconventional parenting made a lasting impression, not just because of the car.
Howard, Warren's middle child, sat down for the interview in New York over Cokes and sandwiches, where he opened up about the unique challenges of growing up with a billionaire father. When he was 18 in 1973, he wanted one thing more than anything else: a brand-new Corvette. But Warren wasn't about to just write a check. Instead, he offered a deal.
Warren agreed to put $5,000 toward the car, but the money would count as Howard's birthday and Christmas presents for three years and his graduation gift. And Howard still had to come up with the remaining $2,500 himself. It was a classic Warren Buffett move – teaching his son that even a dream car came with a price.
See Also: The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a>
Howard took the deal and got his Corvette, but the lessons didn't stop there. Not long after, someone backed into the car. A bystander shrugged it off, saying, "No big deal! <a href="https://www.benzinga.com/personal-finance/24/03/37855579/warren-buffetts-daughter-says-they-lived-like-everybody-else-she-didnt-know-her-dad-was-rich-unt">That's the Buffett kid – </a>there's lots more where that came from." But Howard knew differently. He had to <a href="https://www.benzinga.com/personal-finance/24/09/40881429/warren-buffetts-daughter-asked-him-for-a-41-000-loan-to-remodel-her-kitchen-but-the-billionaire-">pay for the repairs</a> out of his pocket.
Finding his path outside his father's shadow wasn't easy. Like his siblings, Howard bounced between colleges before eventually dropping out. He spent time at Augustana College, Chapman College and the University of California at Irvine but never finished a degree. His journey eventually led him to politics, inspired by his grandfather, Howard Homan Buffett, a Republican congressman whom Warren greatly admired.
In 1988, Howard decided to run for commissioner of the Douglas County Board in Omaha. Before throwing his hat in the ring, he asked his dad whether losing an election would harm his reputation. Warren's response was encouraging and straightforward: "Not at all. People will respect you if you are willing to participate and put yourself on the line."
Trending: <a href="https://www.benzinga.com/money/advisor-adv-warren-buffett">Warren Buffett Flipped His Neighbor's $67,000 Life Savings Into A $50 Million Fortune — This Would Be Worth Over $500 Million Today</a>
However, Warren wasn't about to bankroll the campaign. In true Buffett fashion, he offered to match only 10% of the funds Howard could raise himself. "It was a good solution," Howard said, acknowledging that it pushed him to work harder.
The campaign wasn't without its challenges. At one community meeting in a lower-income neighborhood, Howard worried he'd be dismissed as just another rich kid from West Omaha. He turned to Warren for advice. "Just go down there, shake hands and be friendly," his dad told him. "They're all going to think you're going to be a jerk, so as long as you're not a jerk, you win."
As the interview ended, Howard reflected on his father's influence and their family dynamic. "Our family is close. No one is jockeying for position," he said, adding that Warren's advice and listening ear had been instrumental over the years. But Howard couldn't resist a parting quip about his dad's famously tight grip on money: "Now we'd love to have him loosen up a little!"
For Howard, the Corvette may have been the first deal he struck with his dad, but it certainly wasn't the last – and it left him with <a href="https://www.benzinga.com/money/are-you-rich">more than just a nice car</a>.
Read Next:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li>The number of ‘401(k)' Millionaires is up 43% from last year —<a href="https://www.benzinga.com/money/401k-millionaires"> Here are three ways to join the club.</a></li>
</ul>

Personal Finance

Warren Buffett's Son Wanted A Corvette As A Teen – The Billionaire Gave Him $5,000 Towards It But Said No Other Gifts For 3 Years

Marsh & McLennan's Marsh McLennan Agency Acquires Acumen Solutions Group, Terms Not Disclosed

Across the recent three months, 10 analysts have shared their insights on SM Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SM#NYSE">SM</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated SM Energy and provided 12-month price targets. The average target is $53.1, accompanied by a high estimate of $60.00 and a low estimate of $45.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.12%. 
<img src="https://www.benzinga.com/files/images/story/2025/1735826449_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of SM Energy by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Scialla</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$57.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Hanwen Chang</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>William Janela</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Hanwen Chang</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$47.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$46.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Mike Scialla</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$57.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Gabe Daoud</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$60.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to SM Energy. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of SM Energy compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of SM Energy's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into SM Energy's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on SM Energy analyst ratings.</a>
<h2>Get to Know SM Energy Better</h2>
SM Energy Co is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil and condensate, natural gas, and natural gas liquids. Operating primarily out of the United States, the company actively participates in joint ventures, prospects/leaseholds, and drill-to-earn opportunities. The majority of the company's revenue is derived from some of the United States' premier drilling locations. Drilling location interests have been traditionally obtained through oil and gas leases from third parties. SM Energy relies on its fleet of geologists, geophysicists, landmen, and engineers to help extract the full potential out of all properties held.
<h3>Financial Milestones: SM Energy's Journey</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining SM Energy's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.42% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Energy sector.
Net Margin: SM Energy's net margin is impressive, surpassing industry averages. With a net margin of 37.44%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 6.08%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): SM Energy's ROA stands out, surpassing industry averages. With an impressive ROA of 3.28%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: SM Energy's debt-to-equity ratio stands notably higher than the industry average, reaching 0.67. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SM Energy Stock: A Deep Dive Into Analyst Perspectives (10 Ratings)

Across the recent three months, 11 analysts have shared their insights on Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $129.82, a high estimate of $151.00, and a low estimate of $88.00. A 3.76% drop is evident in the current average compared to the previous average price target of $134.89. 
<img src="https://www.benzinga.com/files/images/story/2025/1735826441_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Blueprint Medicines's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Brian Cheng</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$126.00</td>
<td>-</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$151.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>David Dai</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$88.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Blueprint Medicines. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Blueprint Medicines compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Blueprint Medicines's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Blueprint Medicines's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BPMC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Blueprint Medicines analyst ratings.</a>
<h2>About Blueprint Medicines</h2>
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
<h3>Key Indicators: Blueprint Medicines's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Blueprint Medicines displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 126.61%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Blueprint Medicines's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -43.9%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Blueprint Medicines's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -17.77%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Blueprint Medicines's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -4.68%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Blueprint Medicines's debt-to-equity ratio surpasses industry norms, standing at 1.51. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BPMC

What Analysts Are Saying About Blueprint Medicines Stock

6 analysts have expressed a variety of opinions on Privia Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRVA#NASDAQ">PRVA</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $25.0, a high estimate of $28.00, and a low estimate of $21.00. This upward trend is evident, with the current average reflecting a 4.17% increase from the previous average price target of $24.00.
<img src="https://www.benzinga.com/files/images/story/2025/1735826434_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Privia Health Gr among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Tao Qiu</td>
<td>Macquarie</td>
<td>Announces</td>
<td>Outperform</td>
<td>$25.00</td>
<td>-</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$27.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$23.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Privia Health Gr. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Privia Health Gr compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Privia Health Gr's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Privia Health Gr's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PRVA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Privia Health Gr analyst ratings.</a>
<h2>About Privia Health Gr</h2>
Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.
<h3>Understanding the Numbers: Privia Health Gr's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Privia Health Gr displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 4.95%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Privia Health Gr's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 0.81%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Privia Health Gr's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.58%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.32%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Privia Health Gr's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PRVA

A Glimpse Into The Expert Outlook On Privia Health Gr Through 6 Analysts

Editor&#8217;s Note: The article has been updated with comments from Ryan Air 
A RyanAir Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYAAY#NASDAQ">RYAAY</a>) flight en route from Riga to Vienna had to divert reportedly due to interference with its GPS signal over Poland.
What Happened: A&nbsp;RyanAir&nbsp;flight from Riga to Vienna was forced to divert due to GPS signal interference over Poland, as <a href="https://www.diepresse.com/19215484/ryanair-flug-kann-wegen-gestoerter-gps-signale-nicht-in-wien-landen?ref=ues_a">reported</a> by&nbsp;Die Presse&nbsp;on Tuesday. The flight, identified as FR 748,&nbsp;attempted to land in Vienna&nbsp;twice but was unsuccessful.
The captain of the Airbus A320 announced minor technical issues, causing unrest among passengers. Eventually, the aircraft landed safely in Brno, Czech Republic, where the captain explained that the GPS disruption was linked to the ongoing conflict in Ukraine, a frequent occurrence in the region.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/12/42716303/donald-trump-claims-black-celebrities-were-paid-for-kamala-harris-endorsements?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Donald Trump Claims Black Celebrities Were Paid for Kamala Harris Endorsements</a>
Due to poor visibility, a safe landing in Vienna was not possible without precise positioning, as reported by Die Presse. The weather conditions in Brno were more favorable, allowing for a safe landing, which was met with applause from relieved passengers.
However, the technical issue could not be resolved at Brno airport, necessitating the transport of passengers to Vienna by bus.
&#8220;Flight FR748 from Riga to Vienna yesterday Mon 30 Dec diverted to Bruno due to a minor tech issue with the GPS system combined with low visibility (fog) at Vienna. The aircraft landed normally at Bruno at 22.52 local, where there was no issue with visibility, and passengers were transported by coach to Vienna. We sincerely apologise to passengers for any inconvenience caused as a result of this diversion,&#8221; a spokesperson from Ryan Air told Benzinga. 
Airbus has yet to respond to Benzinga&#8217;s queries.
Why It Matters: The incident involving RyanAir&#8217;s flight FR 748 comes just days after an&nbsp;<a href="https://www.benzinga.com/markets/24/12/42714362/azerbaijan-airlines-flight-hit-by-external-interference-over-russia-before-fatal-crash">Azerbaijan Airlines flight</a>&nbsp;experienced &#8220;external interference&#8221; over Russia, leading to a fatal crash in Kazakhstan. The aircraft, a Brazilian-made Embraer 190, was diverted due to damage sustained during the flight, resulting in 38 casualties. Passengers reported hearing blasts, raising concerns about regional air defense systems.
Additionally, another tragic incident occurred at South Korea&#8217;s&nbsp;<a href="https://www.benzinga.com/general/travel/24/12/42715729/tragic-plane-crash-at-s-koreas-muan-international-airport-181-on-board">Muan International Airport</a>, where a Jeju Air flight crashed during landing, killing several passengers. The B737-800 aircraft collided with the airport's outer runway wall, causing the plane to break apart and subsequently catch fire. The plane was carrying a total of 175 passengers and six crew members.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/24/12/42716153/massive-data-breach-exposes-millions-of-credit-and-debit-cards-is-your-account-safe?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Massive Data Breach Exposes Millions of Credit and Debit Cards—Is Your Account Safe?</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

RYAAY

Days After Two Fatal Crashes, Ryanair Flight To Vienna Diverted Due To Reported GPS Jamming Over Poland (UPDATED)

Starbox Group Holdings Ltd. (STBX) has released an update. Starbox Group Holdings Ltd. has entered a software purchase agreement with Distributed I...

Starbox Group Secures Software Deal with Tech Firms

Starbox Group Holdings Ltd. (STBX) has released an update. Starbox Group Holdings Ltd. has entered into a software purchase agreement involving its...

Starbox Group Boosts Tech Portfolio with Software Acquisition

19:50 EDT Starbox Group (STBX) Holdings Ltd trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-movi...

Starbox Group Holdings Ltd trading halted, news pending

Starbox Group Holdings Ltd. (STBX) has released an update. Starbox Group Holdings Ltd. has successfully completed the acquisition of an Immersive A...

Starbox Group Expands Digital Assets with Strategic Acquisition

Starbox Group Holdings Ltd. (STBX) has released an update. Starbox Group Holdings Ltd. has successfully regained compliance with Nasdaq's minimum b...

Starbox Achieves Nasdaq Compliance, Secures Market Listing

Starbox Group Holdings Ltd. (STBX) has released an update. Starbox Group Holdings Ltd. has entered into a software purchase agreement with Tech Fel...

Starbox Group Acquires Advanced 3D Software Framework

Starbox Group Holdings Ltd. (STBX) has released an update. Starbox Group Holdings Ltd. has entered into a software purchase agreement alongside Fiv...

Starbox Group Facilitates Major Software Acquisition

16:53 EST Starbox Group (STBX) files to sell 20.85M Class A ordinary shares for holders Published first on TheFly – the ultimate source for real-ti...

Starbox Group files to sell 20.85M Class A ordinary shares for holders

Starbox Group Holdings Ltd. (STBX) has released an update. Starbox Group Holdings Ltd. has successfully completed a share issuance and acquisition ...

Starbox Group Completes $9M Share Issuance and Acquisition

Starbox Group Holdings Ltd. (STBX) has released an update. Starbox Group Holdings Ltd. has successfully completed the issuance of 6.1 million Class...

Starbox Group Expands with Strategic Software Acquisition

STBX

Earnings

Press Releases

Starbox Group Holdings Ltd. Announces Financial Results for Fiscal Year 2023

Starbox Launches AI-Driven Digital Human System for Merchants on WeChat Channels, Supporting Its Over 800 Merchants and Over Two Million Existing Users via Live Streaming and Short Videos

AI-Driven Digital Humans System Supporting Thousands of Merchants with Over 2 Million Users (Stock Symbol: STBX)

Starbox Launches "StarboxAI VI-Pro - Live Streaming System": Supporting Starbox's Merchants in Live Streaming Social Commerce

Powerful NASDAQ Listed AI Developer Launches StarboxAI VI-Pro – Live Streaming System; Empowering Over 800 of Merchants to Boost Sales to Over 2 Million Users: StarBox Group (Nasdaq: STBX)

Comments

Starbox Group Hldgs

Noticias

Últimas noticias sobre Starbox Group Hldgs (NASDAQ:STBX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL